Cullinan Therapeutics, Inc.
CGEM
$8.71
$0.202.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -100.17% | -3.51% | -30.47% | 35.91% | 11.12% |
| Total Depreciation and Amortization | 0.00% | -5.00% | -4.94% | 5.56% | 30.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 167.96% | -12.44% | 17.89% | -17.22% | -66.15% |
| Change in Net Operating Assets | 45.65% | 1,117.68% | 75.30% | -600.34% | 166.05% |
| Cash from Operations | -102.01% | 0.01% | -17.05% | 25.00% | 27.43% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.98% | 146.27% | -1,622.43% | -15.56% | 285.02% |
| Cash from Investing | -68.98% | 146.27% | -1,628.59% | -14.67% | 279.90% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 537.90% | 1,668.75% | 589.70% | -- | 27.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -10,633.33% | -- | -- |
| Cash from Financing | 537.90% | 1,083.04% | 579.23% | -39.35% | 100.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -156.81% | 83.20% | 107.01% | 28.86% | 138.83% |
